Mustang driven up as it updates on its CAR-T cell therapy portfolio

19 December 2022

Clinical-stage US biotech Mustang Biotech (Nasdaq: MBIO), which is focused on cell and gene therapies for hematologic cancers, solid tumors and rare genetic diseases, today provided updates on its CAR-T portfolio and 2023 anticipated milestones. The firm’s shares advanced 5.8% to $0.37 following the announcement.

Following lackluster allogeneic CAR-T data presented by multiple companies at ASH, Mustang’s lead clinical candidate, MB-106, has a competitive edge in a market estimated to reach $2.79B by 2030, the company noted.

The CD20-targeted, first-in-class autologous CAR-T cell therapy being evaluated to treat relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL) has generated compelling interim data that compares favorably to the likes of Yescarta [Gilead Sciences’ axicabtagene ciloleucel], odronextamab [from Regeneron Pharmaceuticals] and mosunetuzumab [Roche’s Lunsumio], said Mustang.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK